Browsing by Author Llovet i Bayer, Josep Maria
Showing results 18 to 37 of 45
< previous
next >
| Issue Date | Title | Author(s) |
|---|---|---|
| Mar-2016 | Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis | Sia, Daniela; Villanueva, Augusto; Friedman, Scott L.; Llovet i Bayer, Josep Maria |
| 14-Jun-2018 | Liver Cancer Disparities in New York City: A neighborhood wiew of risk and harm reduction factors | Kamath, Geetanjali R.; Taioli, Emanuela; Egorva, Natalia N.; Llovet i Bayer, Josep Maria; Perumalswami, Ponni V.; Weiss, Jeffrey J.; Schwartz, Myron; Ewala, Stanley; Bickell, Nina A. |
| 1996 | Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial | Forns, Xavier; Ampurdanés, Sergi; Titó Espinagosa, Llúcia; Planas Vilà, Ramon; Viver i Pi-Suñer, Josep M.; Acero i Fernández, Doroteo; Torres Salinas, Miguel; Mas, P.; Morillas Cunill, Rosa María; Forné Bardera, Montserrat; Espinós, J.; Llovet i Bayer, Josep Maria; Costa i Camps, Josep; Olmedo Casas, Eva; López Labrador, Francesc Xavier; Jiménez de Anta Losada, María Teresa; Rodés, J.; Sánchez Tapias, José M. (José María) |
| 23-Jan-2017 | Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity | Moeini, Agrin; Sia, Daniela; Zhang, Zhongyang; Campreciós Figueras, Genís; Stueck, Ashley; Dong, Hui; Montal, Robert; Torrens, Laura; Martínez Quetglas, Iris; Fiel, Maria Isabel; Hao, Ke; Villanueva, Augusto; Thung, Swan N.; Schwartz, Myron; Llovet i Bayer, Josep Maria |
| 7-Mar-2022 | Molecular Characterization and Novel Therapeutic Approaches in Hepatocellular Carcinoma | Torrens Fontanals, Laura |
| 13-May-2021 | Molecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis | Pinyol, Roser; Torrecilla, Sara; Wang, Huan; Montironi, Carla; Piqué Gili, Marta; Torres Martín, Miguel; Wei-Qiang, Leow; Willoughby, Catherine E.; Ramadori, Pierluigi; Andreu Oller, Carmen; Taik, Patricia; Lee, Youngmin A.; Moeini, Agrin; Peix, Judit; Faure-Dupuy, Suzanne; Riedl, Tobias; Schuehle, Svenja; Oliveira, Claudia P.; Alves, Venancio A.; Boffetta, Paolo; Lachenmayer, Anja; Roessler, Sthephanie; Minguez, Beatriz; Schirmacher, Peter; Dufour, Jean François; Thung, Swan N.; Reeves, Helen L.; Carrilho, Flair J.; Chang, Charissa; Uzilov, Andrew V.; Heikenwalder, Mathias; Sanyal, Arun; Friedman, Scott L.; Sia, Daniela; Llovet i Bayer, Josep Maria |
| 2016 | Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition | Nakagawa, Shigeki; Wei, Lan; Song, Won Min; Higashi, Takaaki; Ghoshal, Sarani; Kim, Rosa S.; Bian, C. Billie; Yamada, Suguru; Sun, Xiaochen; Venkatesh, Anu; Goossens, Nicolas; Bain, Gretchen; Lauwers, Gregory Y.; Koh, A. P.; El-Abtah, Mohamed; Ahmad, Noor B.; Hoshida, Hiroki; Erstad, Derek J.; Gunasekaran, Ganesh; Lee, Youngmin; Yu, Ming-Lung; Chuang, Wan-Long; Dai, Chia-Yen; Kobayashi, Masahiro; Kumada, Hiromitsu; Beppu, Toru; Baba, Hideo; Mahajan, Milind; Nair, Venugopalan D.; Lanuti, Michael; Villanueva, Augusto; Sangiovanni, Angelo; Iavarone, Massimo; Colombo, Massimo; Llovet i Bayer, Josep Maria; Subramanian, Aravind; Tager, Andrew M.; Friedman, Scott L.; Baumert, Thomas F.; Schwartz, Myron; Chung, Raymond T.; Tanabe, Kenneth K.; Zhang, Bin; Fuchs, Bryan C.; Hoshida, Yujin; Precision Liver Cancer Prevention Consortium |
| 9-Jul-2019 | Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials | Montal, Robert; Andreu Oller, Carmen; Bassaganyas, Laia; Esteban Fabró, Roger; Moran, Sebastian; Montironi, Carla; Moeini, Agrin; Pinyol, Roser; Peix, Judit; Cabellos, Laia; Villanueva, Augusto; Sia, Daniela; Mazzaferro, Vincenzo; Esteller, Manel; Llovet i Bayer, Josep Maria |
| 1-Jun-2018 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | Pinyol, Roser; Montal, Robert; Bassaganyas, Laia; Sia, Daniela; Takayama, Tadatoshi; Chau, Gar-Yang; Mazzaferro, Vincenzo; Roayaie, Sasan; Lee, Han Chu; Kokudo, Norihiro; Zhang, Zhongyang; Torrecilla, Sara; Moeini, Agrin; Rodriguez-Carunchio, Leonardo; Gane, Edward; Verslype, Chris; Croitoru, Adina Emilia; Cillo, Umberto; de la Mata, Manuel; Lupo, Luigi; Strasser, Simone; Park, Joong-Won; Camps, Jordi; Solé, Manel; Thung, Swan N.; Villanueva, Augusto; Pena, Carol; Meinhardt, Gerold; Bruix Tudó, Jordi; Llovet i Bayer, Josep Maria |
| 30-Jul-2018 | Molecular therapies and precision medicine for hepatocellular carcinoma | Llovet i Bayer, Josep Maria; Montal, Robert; Sia, Daniela; Finn, Richard S. |
| 2-Jul-2014 | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Saha, Supriya K.; Parachoniak, Christine A.; Ghanta, Krishna S.; Fitamant, Julien; Ross, Kenneth N.; Najem, Mortada S.; Gurumurthy, Sushma; Akbay, Esra A.; Sia, Daniela; Cornella, Helena; Miltiadous, Oriana; Walesky, Chad; Deshpande, Vikram; Zhu, Andrew X.; Hezel, Aram F.; Yen, Katharine E.; Straley, Kimberly S.; Travins, Jeremy; Popovici-Muller, Janeta; Gliser, Camelia; Ferrone, Cristina R.; Apte, Udayan; Llovet i Bayer, Josep Maria; Wong, Kwok-Kin; Ramaswamy, Sridhar; Bardeesy, Nabeel |
| 25-Jan-2017 | Objective response by mRECIST as a predictor and potential surrogate end point of overall survival in advanced HCC | Lencioni, Riccardo; Montal, Robert; Torre, Ferran; Park, Joong-Won; Decaens, Thomas; Raoul, Jean-Luc; Kudo, Masatoshi; Chang, Charissa Y.; Ríos, José; Boige, Valerie; Assenat, Eric; Kang, Yoon-Koo; Lim, Ho-Yeong; Walters, Ian; Llovet i Bayer, Josep Maria |
| 14-Nov-2016 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma | Bollard, Julien; Miguela, Verónica; Ruiz de Galarreta, Marina; Venkatesh, Anu; Bian, C. Billie; Roberto, Mark P.; Tovar, Victoria; Sia, Daniela; Molina Sánchez, Pedro; Nguyen, Christie B.; Nakagawa, Shigeki; Llovet i Bayer, Josep Maria; Hoshida, Yujin; Lujambio, Amaia |
| 14-Nov-2020 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab | Reig, María; Galle, Peter R.; Kudo, Masatoshi; Finn, Richard; Llovet i Bayer, Josep Maria; Metti, Andrea L.; Schelman, William R.; Liang, Kun; Wang, Chunxiao; Widau, Ryan C.; Abada, Paolo; Zhu, Andrew X. |
| 27-Jul-2020 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma | Finn, Richard S.; Ikeda, Masafumi; Zhu, Andrew X.; Sung, Max W.; Baron, Ari D.; Kudo, Masatoshi; Okusaka, Takuji; Kobayashi, Masahiro; Kumada, Hiromitsu; Kaneko, Shuichi; Pracht, Marc; Mamontov, Konstantin; Meyer, Tim; Kubota, Tomoki; Dutcus, Corina E.; Saito, Kenichi; Siegel, Abby B.; Dubrovsky, Leonid; Mody, Kalgi; Llovet i Bayer, Josep Maria |
| 15-Nov-2017 | Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria | Llovet i Bayer, Josep Maria; Pavel, Mihai; Rimola, Jordi; Diaz, Maria Alba; Colmenero, Jordi; Saavedra, David; Fondevila Campo, Constantino; Ayuso Colella, Carmen; Fuster Obregón, Josep; Ginès i Gibert, Pere; Bruix Tudó, Jordi; García-Valdecasas Salgado, Juan Carlos |
| Dec-2015 | Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. | Miltiadous, Oriana; Sia, Daniela; Hoshida, Yujin; Fiel, Maria Isabel; Harrington, Andrew N.; Thung, Swan N.; Seng Tan, Poh; Dong, Hui; Revill, Kate; Chang, Charissa Y.; Roayaie, Sasan; Byrne, Thomas J.; Mazzaferro, Vincenzo; Rakela, Jorge; Florman, Sander; Schwartz, Myron; Llovet i Bayer, Josep Maria |
| Aug-2020 | Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Llovet i Bayer, Josep Maria; Finn, Richard S.; Vogel, Arndt; Motomura, Kenta; Assenat, Eric; Merle, Philippe; Brandi, Giovanni; Daniele, Bruno; Okusaka, Takuji; Tomášek, Jiří; Borg, Christophe; Dadduzio, Vincenzo; Morimoto, Manabu; Pracht, Marc; Jen, Min-Hua; Widau, Ryan C.; Shinozaki, Kenta; Yoshikawa, Reigetsu; Zhu, Andrew X. |
| 1-Jan-2020 | Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials | Zhu, Andrew X.; Nipp, Ryan D.; Finn, Richard S.; Galle, Peter R.; Llovet i Bayer, Josep Maria; Blanc, Jean Frederic; Okusaka, Takuji; Chau, Ian; Cella, David; Girvan, Alicia; Gable, Jonathon; Bowman, Lee; Wang, Chunxiao; Hsu, Yanzhi; Abada, Paolo; Kudo, Masatoshi |
| 31-Mar-2019 | Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival | Llovet i Bayer, Josep Maria; Montal, Robert; Villanueva, Augusto |